Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study.

Autor: Matarraz S; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. smats@usal.es.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain. smats@usal.es., Leoz P; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Yeguas-Bermejo A; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., van der Velden V; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Bras AE; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Sánchez Gallego JI; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Lecrevisse Q; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Ayala-Bueno R; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Teodosio C; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Criado I; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., González-González M; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Flores-Montero J; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Avendaño A; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Vidriales MB; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Chillón MC; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., González T; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., García-Sanz R; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Prieto Conde MI; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Villamor N; Hematology Service, Hospital Clinic, Barcelona, Spain., Magnano L; Hematology Service, Hospital Clinic, Barcelona, Spain., Colado E; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Fernández P; FACS/Stem Cell Laboratory, Kantonsspital Aarau, Aarau, Switzerland., Sonneveld E; Dutch Childhood Oncology Group, The Hague, The Netherlands., Philippé J; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium., Reiterová M; CLIP-Department of Pediatric Hematology and Oncology, Second Medical Faculty, Charles University and University Hospital Motol, Prague, Czech Republic., Caballero Berrocal JC; Department of Hematology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Diaz-Gálvez FJ; Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain., Ramos F; Department of Hematology, Complejo Asistencial Universitario de León, León, Spain., Dávila Valls J; Department of Hematology, Complejo Asistencial de Ávila, Ávila, Spain., Manjón Sánchez R; Department of Hematology, Complejo Asistencial de Zamora, Zamora, Spain., Solano Tovar J; Department of Hematology, Complejo Asistencial Universitario de Palencia, Palencia, Spain., Calvo X; Pathology Service, Hospital del Mar, Barcelona, Spain., García Alonso L; Hematology Service, University Hospital of Getafe, Madrid, Spain., Arenillas L; Pathology Service, Hospital del Mar, Barcelona, Spain., Alonso S; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Fonseca A; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Quirós Caso C; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., van Dongen JJM; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Orfao A; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. orfao@usal.es.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain. orfao@usal.es.

Publikováno v: Blood cancer journal [Blood Cancer J] 2023 Sep 04; Vol. 13 (1), pp. 132. Date of Electronic Publication: 2023 Sep 04.